MYNDF News and Press, MYND Life Sciences From 11/09/21

MYND Executes LOI to Enter into a Clinical Research Collaboration with Revitalist Canada NewsWire Focused on generating data through proprietary biomarkers and diagnostic testing of inflammation VANCOUVER, BC , Nov. 9, 2021 /CNW/ - MYND LIFE SCIENCES...

MYND Life Sciences Announces Appointment of New Director PR Newswire VANCOUVER, BC , Oct. 28, 2021 /PRNewswire/ - MYND Life Sciences Inc. (" MYND " or the " Company ") (CSE: MYND) (OTC: MYNDF) announces the following changes to its Board of Direc...

MYND Life Sciences Signs Agreement to Acquire Rights for the Use of Psychedelics to Treat Alzheimer's Disease and other Dementias PR Newswire Acquisition will strengthen MYND's psilocybin-assisted medicinal and diagnostics capabilities, adding novel psychedelics for th...

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations PR Newswire NEW YORK , Oct. 18, ...

MYND Diagnostics Inc. Announces Participation in a Monash University (Australia) Proposal for $3 Million Clinical Trial PR Newswire Evaluating the efficacy of psilocybin-assisted psychotherapy in treatment resistant depression VANCOUVER, BC , Oct. 13, 2...

KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th Canada NewsWire Psychedelic and CNS Company Executives share vision, answer quest...

MYND Life Sciences Inc. to Present at Psychedelics Virtual Investor Conference on October 13 Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com PR Newswire...

MYND Life Sciences Announces Diagnostic Division with Formation of Wholly-Owned Subsidiary - MYND Diagnostics Ltd. PR Newswire MYND Diagnostics was formed to commercialize proprietary biomarker diagnostic tests for patients suffering from MDD, TRD and other psychiatric...